Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade

Abstract

Pulmonary arterial hypertension (PAH) is a rare but well-known cardiovascular condition potentially associated with human immunodeficiency virus (HIV) infection and is currently recognized to be one of the most ominous noninfectious HIV complications. Although there is no clear evidence supporting the use of any medication for the treatment of HIV-related PAH, many of the currently available agents have been shown to exert some clinical benefits HIV-PAH patients. To date, no data are available regarding the potential effects of sitaxsentan, a selective endothelin type-A receptor antagonist, in this peculiar patient population. We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect.

Keywords

HIV infection pulmonary arterial hypertension endothelin receptor antagonists sitaxsentan

References

Archer, S. and Rich, S. (2000) Primary pulmonary hypertension: a vascular biology and translational research `work in progress', Circulation 102: 2781-2791.

Barst, R.J. , Langleben, D. , Badesch, D. , Frost, A. , Lawrence, E.C. , Shapiro, S. et al. for the STRIDE-2 Study Group ( 2006) Treatment of pulmonary arterial hypertension with the selective endothelin-A antagonist sitaxsentan, J Am Coll Cardiol 47: 2049-2056.

Barst, R.J. , Langleben, D. , Frost, A. , Horn, E.M. , Oudiz, R. , Shapiro, S. et al. for the STRIDE-1 Study Group (2004) Sitaxsentan therapy for pulmonary arterial hypertension , Am J Resp Crit Care Med 169: 441-447.

Channick, R.N. , Simonneau, G. , Sitbon, O. , Robbins, I.M. , Frost, A. , Tapson, V.F. et al. (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study, Lancet 358: 1119-1123.

Galiè, N. , Torbicki, A. , Barst, R. , Dartevelle, P. , Haworth, S. , Higenbottam, T. et al. (2004) The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Guidelines on diagnosis and treatment of pulmonary arterial hypertension, Eur Heart J 25: 2243-2278.

Humbert, M. , Morrel, N.W. , Archer, S.L. , Stenmark, K.R. , MacLean, M.R. , Lang, I.M. et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension, J Am Coll Cardiol 43: 13S-24S.

Kedzierski, R.M. and Yanagisawa, M. (2001) Endothelin system: the double-edged sword in health and disease, Ann Rev Pharmacol Toxicol 41: 851-876.

Masaki, T. , Yanagisawa, M. and Goto, K. (1992) Physiology and pharmacology of endothelins, Med Res Rev 12: 391-421.

Mesa, R.A. , Edell, E.S. , Dunn, W.F. and Edwards, W.D. (1998) Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases, Mayo Clin Proc 73: 37-45.

10.

Mehta, N.J. , Khan, I.A. , Mehta, R.N. and Sepkowitz, D.A. (2000) HIV-related pulmonary hypertension: analytic review of 131 cases, Chest 118: 1133-1141.

11.

Pellicelli, A.M. , Barbaro, G. , Palmieri, F. , Girardi, E. , D' Ambrosio, C. , Rianda, A. et al. (2001) Primary pulmonary hypertension in HIV patients: a systematic review, Angiology 52: 31-41.

12.

Rubin, L.J. , Badesch, D.B. , Barst, R.J. , Galie, N. , Black, C.M. , Keogh, A. et al. (2002) Bosentan therapy for pulmonary arterial hypertension, N Engl J Med 346: 896-903.

13.

Simonneau, G. , Galiè, N. , Rubin, L.J. , Langleben, D. , Seeger, W. , Domenighetti, G. et al. (2004) Clinical classification of pulmonary hypertension , J Am Coll Cardiol 43: 5S-12S.

14.

Sitbon, O. , Gressin, V. , Speich, R. , Macdonald, P.S. , Opravil, M. , Cooper, D.A. et al. (2004) Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension, Am J Resp Crit Care Med 170: 1212-1217.

15.

Sitbon, O. , Gressin, V. , Speich, R. , Macdonald, P.S. , Opravil, M. , Cooper, D.A. et al. (1991) Primary pulmonary hypertension in HIV infection , Chest 100: 1268-1271.